Itami, Japan

Shinya Ogino

This inventor holds 5 USPTO granted patents. Top assignee: Senju Pharmaceutical Co., Ltd.. Active years: 1995-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinya Ogino. Retrieved from https://idiyas.com/inventor/shinya-ogino-wyiwacz0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 1995-2001

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Shinya Ogino: Innovator in Pharmaceutical Chemistry

Introduction

Shinya Ogino is a prominent inventor based in Itami, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of antiallergic agents. With a total of 5 patents to his name, Ogino's work has had a notable impact on the industry.

Latest Patents

Among his latest innovations are the Urocanic acid derivatives, which are useful as antiallergic agents. These compounds are represented by a specific formula or a pharmacologically acceptable salt thereof. Another significant invention is a benzylpiperazine derivative, which provides a pharmacologically acceptable salt and is characterized by a complex structure involving various substituents.

Career Highlights

Shinya Ogino is currently associated with Senju Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work focuses on creating effective pharmaceutical solutions that address various health issues.

Collaborations

Ogino has collaborated with notable coworkers, including Kazumi Ogata and Takahiro Sakaue, contributing to a dynamic research environment that fosters innovation.

Conclusion

Shinya Ogino's contributions to pharmaceutical chemistry exemplify the spirit of innovation in the field. His patents and ongoing research continue to pave the way for advancements in antiallergic treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…